Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.74 |
| ▸ | PDE4A | P27815 | 13/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301070 | 0.92 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1302066 | 0.85 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1301884 | 0.78 | PDE4B (0.75) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1301515 | 0.78 | PDE4B (0.75) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1301332 | 0.76 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1301504 | 0.75 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5022238 | 0.75 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1302405 | 0.74 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1301677 | 0.73 | PDE4B (0.76) | PDE4BCYP2C9 | |
| SCHEMBL8298189 | 0.73 | PDE4B (0.62) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | claimed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | claimed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
| EP-2379538-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010084402-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.